Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127406602 | 12740660 | 2 | F | 201212 | 20160926 | 20160914 | 20160929 | EXP | BR-009507513-1608BRA008444 | MERCK | 65.00 | YR | M | Y | 83.00000 | KG | 20160929 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127406602 | 12740660 | 1 | PS | JANUMET | METFORMIN HYDROCHLORIDESITAGLIPTIN PHOSPHATE | 1 | Oral | ONE TABLET AT NIGHT DAILY | 22044 | 1 | DF | FILM-COATED TABLET | QD | ||||||
| 127406602 | 12740660 | 2 | C | METOPROLOL TARTRATE. | METOPROLOL TARTRATE | 1 | Oral | 25 MG, ONE TABLET IN THE MORNING | 0 | 25 | MG | TABLET | QD | ||||||
| 127406602 | 12740660 | 3 | C | DIOVAN | VALSARTAN | 1 | Oral | ONE TABLET IN THE MORNING | 0 | 80 | MG | TABLET | QD | ||||||
| 127406602 | 12740660 | 4 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | ONE TABLET AT NIGHT, UNK | 0 | 10 | MG | TABLET | |||||||
| 127406602 | 12740660 | 5 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 0 | TABLET | ||||||||||
| 127406602 | 12740660 | 6 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 2 TABLETS IN LUNCH TIME | 0 | 200 | MG | QD | |||||||
| 127406602 | 12740660 | 7 | C | JARDIANCE | EMPAGLIFLOZIN | 1 | Oral | 25 MG ONE TABLET IN THE MORNING | 0 | 25 | MG | TABLET | QD | ||||||
| 127406602 | 12740660 | 8 | C | PIOGLITAZONE HYDROCHLORIDE. | PIOGLITAZONE HYDROCHLORIDE | 1 | Oral | 15 MG, ONE TABLET IN THE BREAKFAST TIME | 0 | 15 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127406602 | 12740660 | 1 | Diabetes mellitus |
| 127406602 | 12740660 | 3 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127406602 | 12740660 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127406602 | 12740660 | Blood glucose abnormal | |
| 127406602 | 12740660 | Catheterisation cardiac | |
| 127406602 | 12740660 | Gastrointestinal carcinoma | |
| 127406602 | 12740660 | Metastases to liver | |
| 127406602 | 12740660 | Stent placement |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127406602 | 12740660 | 1 | 201212 | 201608 | 0 | |
| 127406602 | 12740660 | 2 | 201212 | 0 | ||
| 127406602 | 12740660 | 3 | 201212 | 0 | ||
| 127406602 | 12740660 | 6 | 201212 | 0 | ||
| 127406602 | 12740660 | 7 | 2015 | 0 | ||
| 127406602 | 12740660 | 8 | 201212 | 0 |